1
|
Tvedten E, Richardson J, Motaparthi K. What Effect Does Epstein-Barr Virus Have on Extranodal Natural Killer/T-Cell Lymphoma Prognosis? A Review of 153 Reported Cases. Cureus 2021; 13:e17987. [PMID: 34540511 PMCID: PMC8445857 DOI: 10.7759/cureus.17987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/15/2021] [Indexed: 11/09/2022] Open
Abstract
The primary aim of this review is to identify the relationship between Epstein-Barr virus (EBV) and prognosis in extranodal natural killer/T-cell lymphoma (ENKTL). Additionally, a literature review of ENKTL was carried out. The investigators designed and implemented a 21-year literature review using the online databases PubMed and Google Scholar. The total number of cases analyzed was 153 (64 case reports; one comparative study; one systematic review). Information related to ENKTL from July 1999 to February 2021 was included in the study. Study variables included: patient demographics, tumor classification, screening modalities, tumor characteristics, symptomatology, treatment, and prognosis. The average age at diagnosis was 50.9 years (range: 4-90 years). Patients of Asian ethnicity were most commonly affected, and there was a 1.6:1 male to female ratio. ENKTL was most frequently detected in the head and neck region, and 53.1% of cases metastasized. Of all head and neck cases, the nose was the most affected location. Immunohistochemistry positivity included: EBV (32.0%), CD2 (96.6%), CD3ϵ (81.7%), CD43 (91.7%), CD56 (86.4%), Granzyme (97.1%), Perforin (90.9%), TIA-1 (97.8%), p53 (33.3%). The most frequently employed single treatment modality was chemotherapy alone, and 34.2% of patients expired within five years of diagnosis. The average follow-up period was 16.51 months (range: 0.25-66 months). EBV was significantly associated with metastatic ENKTL (χ2 = 4.36; CV = 3.84; p = 0.037). We found no association between EBV and ENKTL prognosis (χ2 = 17.2; CV = 21.0; p = 0.14).
Collapse
Affiliation(s)
- Erika Tvedten
- Department of Dermatology, Michigan State University, Detroit, USA
| | | | - Kiran Motaparthi
- Department of Dermatology, University of Florida, Gainesville, USA
| |
Collapse
|
2
|
Lyons LJ, Vrcek I, Somogyi M, Taheri K, Admirand JH, Chexal S, Loukas DF, Nakra T. Natural killer/T-cell lymphoma invading the orbit and globe. Proc (Bayl Univ Med Cent) 2017; 30:447-449. [PMID: 28966461 DOI: 10.1080/08998280.2017.11930224] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
Natural killer/T-cell lymphomas are extremely rare and carry high mortality rates. Epidemiologically, these cancers tend to affect mainly Asian and South American patients and are associated with Epstein-Barr virus seropositivity. This report details a 78-year-old Vietnamese woman who presented initially with vitritis of unknown cause, but later developed proptosis and conjunctival involvement as her disease spread. Biopsies of the orbit, ethmoid sinus, and conjunctiva were found to be significant for natural killer/T-cell lymphoma. The case highlights the diagnostic difficulty of this tumor given its rarity and ability to mimic other disorders.
Collapse
Affiliation(s)
- Lance J Lyons
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Ivan Vrcek
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Marie Somogyi
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Kevin Taheri
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Joan H Admirand
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Saradha Chexal
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Demetrius F Loukas
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| | - Tanuj Nakra
- University of Texas at Austin Dell Medical School, Austin, Texas (Lyons); TOC Eye and Face, Austin, Texas (Vrcek, Somogyi, Nakra); ENT and Allergy Center of Austin, Round Rock, TX (Taheri); Seton Medical Center Austin, Austin, Texas (Admirand); Retina Consultants of Austin, Austin, Texas (Chexal); and Texas Oncology, Austin, Texas (Loukas)
| |
Collapse
|
3
|
Wang X, Gong Z, Li SX, Yan W, Song Y. Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature. BMC Urol 2017; 17:77. [PMID: 28874193 PMCID: PMC5585933 DOI: 10.1186/s12894-017-0273-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 08/31/2017] [Indexed: 01/28/2023] Open
Abstract
Background Extranodal natural killer/T-cell lymphoma (ENKTL) usually presents as a localized disease in the nasal cavity; extension to the male genitourinary system is very rare and has been characterized only recently. Most cases present with predominantly extranodal involvement, advanced stage disease, highly aggressive course, and strong association with Epstein-Barr virus (EBV). While metastasis is common in ENKTLs, the penis is rarely involved in both nasal and non-nasal ENKTLs and only one report was published to date. Case presentation One patient with NK/T-cell lymphoma, presented initially with a penile mass, is reported. The 58-year-old man who presented with progressive painless penile swelling underwent penectomy for penile tumor. Histologically, the glans and foreskin revealed neoplastic infiltration of medium-sized lymphoma cells expressing CD56, CD3, granzyme-B, and labeled for EBV-encoded RNA in situ hybridization. Findings were consistent with NK/T-cell lymphoma. By detailed history, we learned that the patient had nasal obstruction for more than 10 years. Nasopharyngeal involvement was screened with PET-CT; ENKTL was diagnosed after a nasopharyngeal biopsy. The final diagnosis was primary nasal NK/T-cell lymphoma, with metastasis to the penis. Additional sites of disease appeared soon afterward (adrenal gland, liver, spleen and lymph nodes). The patient died within 4 months. Conclusion This study suggested that penile NK/T-cell lymphoma tends to disseminate early and pursues an aggressive course. It is imperative to distinguish nasal NK/T lymphoma from other types of tumors, because the prognosis and treatment differ significantly for secondary metastases.
Collapse
Affiliation(s)
- Xiaotian Wang
- Department of Urology, Shengjing Hospital of China Medical University, 36 Saohao Road, Shenyang, Liaoning, China
| | - Zimu Gong
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
| | - Shawn Xiang Li
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.,International College, China Medical University, Shenyang, China
| | - Wei Yan
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
| | - Yongsheng Song
- Department of Urology, Shengjing Hospital of China Medical University, 36 Saohao Road, Shenyang, Liaoning, China.
| |
Collapse
|
4
|
RAP1B, a DVL2 binding protein, activates Wnt/beta-catenin signaling in esophageal squamous cell carcinoma. Gene 2017; 611:15-20. [PMID: 28119087 DOI: 10.1016/j.gene.2017.01.021] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Revised: 01/15/2017] [Accepted: 01/20/2017] [Indexed: 11/22/2022]
Abstract
RAP1B is a small GTPase, which regulates multiple cellular processes. Up-regulation of RAP1B has been observed in several cancer types. Although previous study has shown that miR-518 inhibited the proliferation and invasion of esophageal squamous cell carcinoma (ESCC) cells possibly by targeting RAP1B, the expression pattern and the functions of RAP1B in ESCC are not fully understood. Here, we have fund that the expression of RAP1B was up-regulated in ESCC clinical samples. Gain-of-function and loss-of-function assays demonstrated that RAP1B promoted the growth, migration and metastasis of the ESCC cells. Moreover, the mechanism study showed that RAP1B interacted with DVL2, an important upstream regulator for beta-catenin/TCF signaling, and activated beta-catenin/TCF signaling. Taken together, our study demonstrated the oncogenic roles of RAP1B in ESCC, and suggested that RAP1B might be a therapeutic target.
Collapse
|